[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Harvard Medical School (HMS and HSDM)\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":262},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,45,76,98,124,150,180,206,236],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100626797","star-matrix-vs-autogenous-graft-for-gingival-augmentation-split-mouth-rct-100626797",false,"NCT07440303","Star Matrix vs Autogenous Graft for Gingival Augmentation: Split-Mouth RCT","The Clinical Efficacy of Star Matrix Versus Autogenous Gingival Graft in Augmenting Keratinized Tissue Around Teeth- A Split-mouth Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* Adults 20 - 80 years old who need gingival augmentation on both sides of the lower jaw.\n* Able and willing to sign the consent form, follow study instructions and return for all visits\n* Generally healthy (no significant illnesses or medicines that could interfere with healing).\n* Demonstrates good daily oral hygiene (low plaque levels at baseline).\n\nExclusion Criteria:\n\n* Does not meet any of the inclusion points or is unlikely to follow the schedule\n* Previous gingival graft at the study site that failed\n* Needs a root-coverage (recession-repair) procedure instead of simple width augmentation\n* Active, untreated gum disease, cavities, infection, or chronic inflammation near the study teeth\n* Used cigarettes, e-cigarettes, or other nicotine products within 3 weeks\n* Insulin-dependent diabetes or hemoglobin A1c \\> 6.5 %\n* Cancer (other than minor skin cancers or in-situ cervical cancer) within the past 5 years\n* Currently pregnant or breastfeeding\n* Taking (or soon to begin) drugs that change bone turnover (e.g., bisphosphonates, steroids)\n* Diseases that disturb bone metabolism (except common osteoporosis)\n* Auto-immune disease or known allergy to porcine collagen or study materials\n* Active infection at the planned graft site\n* Current use of systemic blood thinners (anticoagulants or antiplatelet agents; e.g., warfarin, heparin\u002FLMWH, DOACs such as apixaban\u002Frivaroxaban\u002Fdabigatran\u002Fedoxaban, or P2Y12 inhibitors such as clopidogrel\u002Fprasugrel\u002Fticagrelor)",true,"ALL","20 Years","80 Years",{"count":21,"type":22},12,"ESTIMATED","INTERVENTIONAL",[25],"NA","This split-mouth randomized controlled clinical trial will test whether a ready-to-use collagen membrane (Star Matrix) can widen the protective band of gum tissue (keratinized gingiva) as effectively as the standard free gingival graft harvested from the palate.\n\nCentral question Can Star Matrix provide the same or better gain in keratinized tissue width-with less patient discomfort and chair-time-than an autogenous graft?\n\nPrimary objectives\n\nCompare the 6-month increase in keratinized tissue width between Star Matrix and autogenous graft sites.\n\nAssess patient-reported pain and morbidity associated with each treatment.\n\nSecondary objectives\n\nMeasure operative time, early healing scores, esthetic outcomes, and (optional) histologic quality of the regenerated tissue.\n\nMethods Twelve adults with ≤ 2 mm keratinized tissue on contralateral lower-jaw teeth will be enrolled. Each participant receives Star Matrix on one side and a conventional free gingival graft on the other. Follow-up visits at 2, 4, 8, 12 and 24 weeks include clinical measurements, standardized photographs, and a 7-day postoperative pain diary. An optional 2 mm punch biopsy at 6 months is analyzed microscopically.",[28,29],"Lack of Keratinized Gingiva","Mucogingival Deformity - Insufficient Keratinized Tissue",[31],"mucogingival deformity","RECRUITING","2026-02-23",{"date":35,"type":36},"2026-02-27","ACTUAL",{"date":38,"type":36},"2025-11-06",{"date":40,"type":22},"2026-10-01",{"name":42,"class":43},"Harvard Medical School (HMS and HSDM)","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":16,"sex":17,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":23,"phases":54,"briefSummary":55,"conditions":56,"keywords":60,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":4},"100519456","digital-implementation-support-to-achieve-uptake-and-integration-of-task-shared-care-for-schizophrenia-in-primary-care-in-india-100519456","NCT06043778","Digital Implementation Support to Achieve Uptake and Integration of Task-Shared Care for Schizophrenia in Primary Care in India","Inclusion Criteria:\n\n* Primary diagnosis of schizophrenia per IDC-10 diagnostic criteria for research and an illness duration of greater than 12 months and overall moderate level of severity on the CGI-SCH scale\n* At least one risk factor for early mortality (e.g. hypertension, diabetes, dyslipidemia, etc)\n* Willingness to stay in the study area during the trial period\n* Ability to operate a smartphone\n\nExclusion Criteria:\n\n* Major visual impairment or inability to operate a smartphone\n* Cognitive impairment or diagnosis of dementia\n* Planning to move out of the study area in the next 12 months\n* Does not speak Hindi or Kannada","18 Years",{"count":53,"type":22},240,[25],"Schizophrenia represents a significant contributor to the global burden of disease, with this burden disproportionately impacting low- and middle-income countries (LMICs). In India, the burden due to schizophrenia is further exacerbated by low access to effective psychosocial interventions aimed at promoting recovery, rehabilitation, and community tenure, as well as inadequate attention to managing co-occurring chronic medical conditions that result in significantly reduced life expectancy among those living with schizophrenia compared to the general population. A major driver of these alarming gaps in access to care for persons with schizophrenia in India is the limited capacity within primary care settings aimed at addressing the complex co-occurring mental health, physical health, and functional needs of this patient population. There now exists strong evidence demonstrating that community programs delivered in primary care and leveraging psychosocial interventions combined with linkage to specialty psychiatric services are effective for supporting treatment and recovery of schizophrenia in low-resource settings. We will leverage our existing collaboration and robust research infrastructure in both rural and urban settings in Madhya Pradesh and Karnataka, India to conduct a hybrid type 1 effectiveness-implementation trial to evaluate whether the use of a digital platform offers added clinical benefit and can support integration of this task shared care for schizophrenia into routine primary care settings. We will address the following aims: 1) evaluate whether the use of the mindLAMP digital platform can enhance the clinical effectiveness of task-shared community-based psychosocial rehabilitation (COPSI) for individuals with schizophrenia, and 2) determine whether the addition of mindLAMP to the delivery of the COPSI program has an impact on implementation metrics when compared to delivery of COPSI alone.",[57,58,59],"Schizophrenia","Schizophrenia and Related Disorders","Psychosocial Functioning",[61,62,63,64,65,66],"schizophrenia","psychosocial intervention","digital technology","task sharing","implementation","smartphone app","NOT_YET_RECRUITING","2026-02-10",{"date":70,"type":36},"2026-02-12",{"date":72,"type":22},"2026-07",{"date":74,"type":22},"2029-03-31",{"name":42,"class":43},{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":16,"sex":17,"minAge":51,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":23,"phases":86,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":44},"100495317","vertical-soft-tissue-augmentation-with-ctg-vs-adm-100495317","NCT05729607","Vertical Soft Tissue Augmentation With CTG vs ADM","Vertical Soft Tissue Augmentation With Dermal Matrix and Enamel Matrix Derivative vs Connective Tissue Graft for the Treatment of Peri-implant Soft Tissue Dehiscences in the Esthetic Zone: A Randomized, Controlled, Clinical, Trial","Inclusion criteria:\n\n* Age ≥ 18 years\n* Periodontally and systemically healthy\n* Full-mouth plaque score and full-mouth bleeding score ≤ 20% (measured at four sites per tooth)\n* Presence of single functional dental implant in the anterior with a PSTD\n* Implants diagnosed as healthy (Berglundh et al., 2018)\n\nExclusion criteria are:\n\n* Contraindications for surgery\n* Systemic condition (e.g. diabetes mellitus, HIV, cancer, etc) that could compromise wound healing\n* Patients pregnant or attempting to get pregnant (self-reported)\n* Untreated periodontitis\n* Untreated peri-implant mucositis or peri-implantitis (Berglundh et al., 2018)\n* Smoking, defined as self-reported daily habit. Occasional smokers won't be excluded\n* History of soft tissue grafting at the implant site within the last 6 months","99 Years",{"count":85,"type":22},28,[25],"The study aims at comparing two different approaches for vertical soft tissue augmentation at implant sites exhibiting soft tissue dehiscences: autogenous connective tissue graft vs acellular dermal matrix + enamel matrix derivative",[89],"Implant Complication","2025-09-12",{"date":92,"type":36},"2025-09-18",{"date":94,"type":36},"2023-05-26",{"date":96,"type":22},"2027-11-27",{"name":42,"class":43},{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":16,"sex":17,"minAge":51,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":23,"phases":106,"briefSummary":107,"conditions":108,"keywords":113,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":4},"100605201","multimodal-radiology-report-to-improve-patient-centered-radiology-100605201","NCT07159438","Multimodal Radiology Report to Improve Patient-centered Radiology","Inclusion Criteria:\n\n* Age 18+ adults who have taken a radiology examination.\n\nExclusion Criteria:\n\n* N\u002FA",{"count":105,"type":22},200,[25],"The goal of this study is to learn if AI-generated video explanations help people better understand their radiology reports. The main question it aims to answer is:\n\nDo AI-generated videos help participants understand their medical imaging results better than written reports alone? Participants will send their own radiology images and written reports to the research team; receive a personalized AI-generated video that explains their results in easy-to-understand language; watch their video explanation (about 1-5 minutes long); and complete 15-minute online survey about how well the video helped them understand their results.",[109,110,111,112],"Health Literacy","Diagnostic Imaging","Imaging Results","Artificial Intelligence",[114,115,112],"Patient-centered Understanding","Radiology Reports","2025-08-28",{"date":118,"type":36},"2025-09-08",{"date":120,"type":22},"2026-12",{"date":122,"type":22},"2028-12",{"name":42,"class":43},{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":131,"targetDuration":4,"studyType":23,"phases":133,"briefSummary":134,"conditions":135,"keywords":137,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":149},"100599928","additively-versus-subtractively-manufactured-implant-supported-fixed-dental-prostheses-100599928","NCT07090863","Additively Versus Subtractively Manufactured Implant Supported Fixed Dental Prostheses","Additively (AM) Versus Subtractively (SM) Manufactured Implant Supported Fixed Dental Prostheses (iFDPs)","Inclusion Criteria:\n\n* Signed Informed Consent Form in English language\n* ≥ 20 years of age\n* In need of at least one definitive screw retained premolar or molar iFDP on an existing dental implant (Straumann AG)\n* Presence of at least one adjacent tooth at the implant site\n* Adequate oral hygiene\n* Capability to comply with the study procedures\n\nExclusion Criteria:\n\n* Pregnant or lactating women\n* Known or suspected non-compliance, drug or alcohol abuse\n* Severe periodontal and peri-implant disease",{"count":132,"type":22},50,[25],"This research is being done to evaluate the clinical, technical, biological, and aesthetic results of two different fabrication methods (additive and subtractive) for creating implant-supported fixed dental prostheses (iFDPs). Patients will receive an iFDP, meaning an implant-supported crown, according to regular treatment protocols. The fabrication method used to create the implant-supported crown will be decided in a randomised way. Clinical and radiological examinations will be performed prior to and when receiving the implant-supported crown and during a follow-up period of 3 years. Furthermore, technician- and patient-reported outcomes will be evaluated used questionnaires.",[136],"Dental Prosthesis, Implant-Supported",[138,139,140],"3D-printing","implant-supported prostheses","additive manufacturing","2025-07-31",{"date":143,"type":36},"2025-08-05",{"date":145,"type":22},"2025-07-30",{"date":147,"type":22},"2029-07-20",{"name":42,"class":43},2,{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":156,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":17,"minAge":51,"maxAge":158,"enrollmentInfo":159,"targetDuration":4,"studyType":23,"phases":161,"briefSummary":162,"conditions":163,"keywords":165,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":149},"100562390","robotic-apparel-to-prevent-freezing-of-gait-in-parkinson-disease-100562390","NCT06602544","Robotic Apparel to Prevent Freezing of Gait in Parkinson Disease","Preventing Freezing of Gait in Parkinson's Disease Using Soft Robotic Apparel","XF","Inclusion Criteria:\n\n* 18-90 years old\n* Self-reported Freezing of Gait due to PD\n* Score of 21 or higher on the cognitive screening test (Montreal Cognitive Assessment Score (MoCA))\n* Independent ambulation (with or without an assistive device, no physical assistance) for at least 20 meters\n* Able to understand, communicate, and be understood by study staff\n* Provide HIPAA Authorization to allow communication with the participant's treating physician\u002Fprovider for medical clearance (if deemed necessary by study clinical team) to verify self-reported medical history (if deemed necessary by study clinical team)\n* Provide informed consent\n* Ability to participate in 8 research study visits\n\nExclusion Criteria:\n\n* More than 2 falls in the previous month, as a result of gait impairment (may enroll under clinician discretion)\n* Major surgery in the last 6 months that interferes with walking (may enroll under clinician discretion)\n* Gait deficits due to missing limbs\n* Experience chronic pain that interferes with walking ability (may enroll under clinician discretion)\n* Serious co-morbidities (unrelated to gait impairment) that may interfere with ability to participate in research (e.g. cardiovascular, neurological, skin, and vascular conditions such as acute, ongoing\u002Funmanaged deep vein thrombosis)\n* No observable freezing-of-gait","90 Years",{"count":160,"type":22},20,[25],"Freezing-of-gait (FoG) in Parkinson Disease (PD) is one of the most vivid and disturbing gait phenomena in neurology. Often described by patients as a feeling of \"feet getting glued to the floor,\" FoG is formally defined as a \"brief, episodic absence or marked reduction of forward progression of the feet despite the intention to walk.\" This debilitating gait phenomena is very common in PD, occurring in up to 80% of individuals with severe PD. When FoG arrests walking, serious consequences can occur such as loss of balance, falls, injurious events, consequent fear of falling, and increased hospitalization. Wearable robots are capable of augmenting spatiotemporal gait mechanics and are emerging as viable solutions for locomotor assistance in various neurological populations. For the proposed study, our goal is to understand how low force mechanical assistance from soft robotic apparel can best mitigate gait decline preceding a freezing episode and subsequent onset of FoG by improving spatial (e.g. stride length) and temporal features (e.g. stride time variability) of walking. We hypothesize that the ongoing gait-preserving effects can essentially minimize the accumulation of motor errors that lead to FoG. Importantly, the autonomous assistance provided by the wearable robot circumvents the need for cognitive or attentional resources, thereby minimizing risks for overloading the cognitive systems -- a known trigger for FoG, thus enhancing the repeatability and robustness of FoG-preventing effects.",[164],"Parkinson Disease (PD)",[166,167,168,169,170,171],"Parkinson Disease","Freezing-of-gait","Wearable Robot","Soft Robotics","Gait","Rehabilitation","2025-07-15",{"date":174,"type":36},"2025-07-18",{"date":176,"type":36},"2024-09-03",{"date":178,"type":22},"2027-09",{"name":42,"class":43},{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":4,"eligibilityCriteria":186,"healthyVolunteers":16,"sex":17,"minAge":51,"maxAge":187,"enrollmentInfo":188,"targetDuration":4,"studyType":23,"phases":190,"briefSummary":191,"conditions":192,"keywords":195,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":205,"locationsCount":44},"100430726","the-effect-of-work-requirements-in-snap-in-virginia-100430726","NCT04888832","The Effect of Work Requirements in SNAP in Virginia","Disparities in Medicaid and SNAP Participation: the Effects of Work Requirements and the COVID-19 Pandemic","Inclusion Criteria:\n\n* Eligible for Virginia's SNAP program as an \"able-bodied adult without dependents\" (ABAWD) and thus subject to work requirements (this eligibility is age restricted to 18-49)\n\nExclusion Criteria:\n\n* Categorical exemption from work requirements for any reason (e.g., has a disability, has dependents, resides in a geographic area where work requirements have been waived due to elevated employment)","49 Years",{"count":189,"type":22},12500,[25],"More than a dozen states have proposed or plan to implement work requirements in Medicaid, and similar requirements already exist nationally in the Supplemental Nutritional Assistance Program (SNAP), yet evidence on the effects of these policies is limited. In cooperation with the state of Virginia, the investigators plan to conduct a randomized controlled trial studying the impacts of work requirements in public programs on insurance coverage, SNAP participation, employment, and health, with a particular focus on changes in racial\u002Fethnic and geographic disparities in these outcomes. The COVID-19 epidemic and concurrent economic downturn creates additional urgency around these issues, and the investigators will use a combination of national administrative data and a new population survey to assess disparities in employment, health care, and food insecurity during this crisis.",[193,194],"Health Disparities","Food Security",[196,197,198],"Supplemental Nutrition Assistance Program","work requirements","Medicaid","2025-02-28",{"date":201,"type":36},"2025-03-05",{"date":203,"type":36},"2024-04-01",{"date":120,"type":22},{"name":42,"class":43},{"id":207,"slug":208,"hasResults":11,"nctId":209,"briefTitle":210,"officialTitle":210,"acronym":4,"eligibilityCriteria":211,"healthyVolunteers":16,"sex":17,"minAge":51,"maxAge":4,"enrollmentInfo":212,"targetDuration":4,"studyType":23,"phases":214,"briefSummary":215,"conditions":216,"keywords":222,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":44},"100558662","soft-tissue-response-to-different-restorative-materials-used-in-implant-dentistry-100558662","NCT06554041","Soft Tissue Response to Different Restorative Materials Used in Implant Dentistry","Inclusion Criteria:\n\n* Participants must be 18 years or older.\n* Participants must be edentulous with at least four missing teeth in the posterior region of the mandible or maxillae.\n* Participants must have appropriate oral hygiene and periodontal status of natural teeth, with a pocket depth of 4mm or less and no bleeding.\n* Dental implants must be fully integrated with no bone resorption or inflammation after three months of implant placement, confirmed by X-ray and clinical examination.\n* Implant placement must be into natural bone without additional procedures such as sinus lift or bone augmentation.\n* The procedure must be a standard implantation with no immediate implant placement.\n* The height of the gingiva must be at least 3mm or more.\n\nExclusion Criteria:\n\n* Patients with systemic diseases such as malignancy, diabetes, osteoporosis, or rheumatoid arthritis.\n* Patients with a history of periodontal treatment.\n* Patients who smoke or use tobacco.\n* Patients who have received antibiotic treatment within three months prior to implantation.\n* Pregnant individuals.",{"count":213,"type":22},40,[25],"The goal of this clinical trial is to learn how different materials used in dental implants affect the surrounding gum tissue in adults who need dental implants. The main questions it aims to answer are:\n\nHow do different materials (titanium, PEEK, zirconia, and lithium disilicate) affect inflammation around dental implants? What changes occur in inflammation markers in the gum tissue after 3 and 6 months? Researchers will compare the different materials to see which one causes the least amount of inflammation.\n\nParticipants will:\n\nReceive dental implants made from different materials. Have samples of fluid from around their implants collected for analysis at 3 and 6 months.\n\nUndergo regular dental check-ups to measure gum health, such as bleeding and pocket depth around the implants.",[217,218,219,220,221],"Edentulous Alveolar Ridge","Peri-Implantitis","Peri-implant Mucositis","Prosthetic Infection","Prosthetic Complication",[223,224,225,226,227],"Dental Implants","Peri-Implant Soft Tissue","Prosthetic Materials","Inflammation Markers","Oral Health","2024-08-12",{"date":230,"type":36},"2024-08-14",{"date":232,"type":36},"2023-08-23",{"date":234,"type":22},"2026-01-01",{"name":42,"class":43},{"id":237,"slug":238,"hasResults":11,"nctId":239,"briefTitle":240,"officialTitle":241,"acronym":4,"eligibilityCriteria":242,"healthyVolunteers":11,"sex":17,"minAge":51,"maxAge":243,"enrollmentInfo":244,"targetDuration":4,"studyType":23,"phases":246,"briefSummary":247,"conditions":248,"keywords":250,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":261,"locationsCount":4},"100552697","use-of-facilitated-stair-coach-in-kenya-100552697","NCT06476457","Use of Facilitated STAIR Coach in Kenya","Low Cost, Low Intensity, Mobile-based Trauma Intervention (Facilitated STAIR Coach) for Use in Kenya","Inclusion Criteria:\n\n* criteria\n\n  1. 18 years of age or older\n  2. ability to complete the study in English\n  3. agreed to be contacted for follow-up studies when consenting to the parent study\n  4. not currently enrolled in another form of psychotherapy\n  5. if currently prescribed medications, participants must be on a stable dosage of psychotropic medications (i.e., prescribed on stable dose for 1 month or more)\n  6. have a score of 33 or higher on the PCL-5 lifetime score in the parent study\n\n     Exclusion Criteria:\n\n  \u003C!-- -->\n\n  1. less than 18 years of age\n  2. unable to complete the study in English\n  3. did not agree to be contacted for follow-up studies when consenting to the parent study\n  4. diagnosed with a psychotic disorder, unmedicated bipolar disorder, or severe substance-use disorder\n  5. experiencing ongoing long-term trauma as it is a contraindication for trauma focused treatment\n  6. experiencing acute levels of alcohol or is under the influence of an illegal substance, demonstrated by inpatient medical care for alcohol or substance abuse\n  7. participant is not competent to consent to the study as measured by the UBACC in the parent study\n  8. During parent study assessment (IRB23-0211), the participant receives a PCL score less than 33\n  9. Participant is receiving inpatient psychiatric care at the time of the study or experiencing involuntary detention","65 Years",{"count":245,"type":22},10,[25],"The specific aim of this project is to examine the feasibility of using a low cost, low intensity, mobile app-based intervention teaching emotion regulation and interpersonal skills to improve general well-being for those with probable post-traumatic stress disorder (PTSD) in Kenyan clinics.",[249],"Facilatated STAIR Coach",[251,252,253],"STAIR","STAIR Coach","post-traumatic stress disorder","2024-06-21",{"date":256,"type":36},"2024-06-26",{"date":258,"type":22},"2024-12-01",{"date":260,"type":22},"2025-12-31",{"name":42,"class":43},""]